این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
International Journal of Hematology-Oncology and Stem Cell Research، جلد ۱۹، شماره ۲، صفحات ۱۵۱-۱۵۷
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی ESHAP versus IEV Chemotherapy for Relapsed or Refractory Hodgkin's and Non- Hodgkin's Lymphoma
چکیده انگلیسی مقاله Background: High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard treatment for Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL) in cases of relapsed or refractory disease. Various salvage chemotherapy regimens have been introduced with specific response rates, toxicity profiles, costs, and stem cell damage before stem cell harvest. The optimal salvage regimen for these patients is unclear. Materials and Methods: In this retrospective analysis, 276 patients with HL and NHL with relapsed or refractory disease after initial treatment that received ESHAP (etoposide, methylprednisolone, cytosine arabinoside, and platinum) or IEV (ifosfamide, epirubicin, etoposide) as salvage regimen were included. We aimed to compare the efficacy of these two chemotherapy regimens as a life-saving treatment in recurrent or refractory disease. Results: The mean age of patients was 33.96 ± 12.39 years. Hodgkin's lymphoma accounted for 60.1% and non-Hodgkin lymphoma (DLBCL) accounted for 39.9% of patients. The overall response rate (ORR) was 79.8% (50% complete response (CR)) for patients with Hodgkin lymphoma who received the ESHAP and 85.6% (55.1% CR) for the IEV regimen. Patients with non-Hodgkin's lymphoma who received the ESHAP plus rituximab regimen had an ORR of 60.9% (CR 40.3%), and patients who received the IEV + Rituximab chemotherapy regimen had an ORR of 72.4% (CR 42.4%) (P = 0.03). However, the mortality rate was lower in patients who received the IEV chemotherapy regimen. Conclusion: IEV treatment is superior to ESHAP in patients with recurrent or refractory Hodgkin's and non-Hodgkin's lymphoma.
کلیدواژه‌های انگلیسی مقاله
نویسندگان مقاله | Mehdi Dehghani
Hematology Research Center, Department of Hematology and Medical Oncology, Shiraz University of Medical Sciences, Shiraz, Iran


| Reza Vojdani
Hematology Research Center, Department of Hematology and Medical Oncology, Shiraz University of Medical Sciences, Shiraz, Iran


| Abolfazl Khalafi-Nezhad
Department of Hematology and Medical Oncology, Shiraz University of Medical Sciences, Shiraz, Iran


| Mohammad Reza Ravanbod
Department of Hematology and Medical Oncology, Shiraz University of Medical Sciences, Shiraz, Iran


| Mani ramzi
Hematology Research Center, Department of Hematology and Medical Oncology, Shiraz University of Medical Sciences, Shiraz, Iran


| Shima Dehdashti
Department of Hematology and Medical Oncology, Shiraz University of Medical Sciences, Shiraz, Iran


| Nasrin Namdari
Department of Hematology and Medical Oncology, Shiraz University of Medical Sciences, Shiraz, Iran
نشانی اینترنتی https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/2114
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات